Dear Ms. Oliynyk:

Please refer to your supplemental new drug application (sNDA) dated and received January 10, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DEXTENZA (dexamethasone ophthalmic insert), 0.4 mg, for intracanalicular use. This Prior Approval supplemental new drug application provides for the treatment of ocular inflammation following ocular surgery.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling, which is identical to the labeling submitted on June 19, 2019, but with the addition of a vertical line in the left margin beside Section 1 INDICATIONS AND USAGE.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling text for the prescribing information.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.² The SPL will be accessible from publicly available labeling repositories.

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
REQUIRED PEDIATRIC ASSESSMENTS
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are deferring the submission of your pediatric study until April 2023, as listed in our November 30, 2018, approval letter for your NDA because this product is ready for approval for use in adults and the pediatric study has not been completed.

PROMOTIONAL MATERIALS
You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵ For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.⁶

³ When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/UCM083570.pdf
⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/UCM375154.pdf
⁶ http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
REPORTING REQUIREMENTS
We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Chief, Project Management Staff at 301-796-0763.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, MD
Deputy Director
Division of Transplant and Ophthalmology Products
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE: Prescribing Information
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILEY A CHAMBERS
06/20/2019 04:38:08 PM